Evidence map›Paper›PMID 41645347›Full record

ArticleJournal of cannabis research2026

Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents.

Ferenc Dániel Petróczi, Angéla Tótik, Miklós Bege, József Király, Erzsébet Szabó, Zsuzsanna Szabó, Nikoletta Dobos, Rasha Ghanem Kattoub, Charu Upadhyay, Eszter Ostorházi and 13 more

Abstract read
In one paragraph

Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ferenc Dániel PetrócziDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary.
Angéla TótikDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary.
Miklós BegeDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary.
József KirályDepartment of Biopharmacy, University of Debrecen, Rex Ferenc utca 1, Debrecen, H-4002, Hungary.
Erzsébet SzabóDepartment of Pharmacology, University of Debrecen, Rex Ferenc utca 1, Debrecen, H-4002, Hungary.
Zsuzsanna SzabóDepartment of Biopharmacy, University of Debrecen, Rex Ferenc utca 1, Debrecen, H-4002, Hungary.
Nikoletta DobosDepartment of Biopharmacy, University of Debrecen, Rex Ferenc utca 1, Debrecen, H-4002, Hungary.
Rasha Ghanem KattoubDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary.
Charu UpadhyayLaboratory for Translational Chemistry and Drug Discovery, Department of Chemistry, Hansraj College, University of Delhi, Delhi, India.
Eszter OstorháziDepartment of Medical Microbiology, Semmelweis University, Nagyvárad tér 4, Budapest, H-1089, Hungary.
Jan HodekInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Science, Prague, Prague, Czech Republic.
Jan WeberInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Science, Prague, Prague, Czech Republic.
József AranyDepartment of Physiology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
Dorottya ÁdámDepartment of Physiology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
Christos C ZouboulisDepartments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, Germany.
Attila OláhDepartment of Physiology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary.
István BajzaGlycOptim Kft., Egyetem tér 1, Debrecen, H-4032, Hungary.
Árpád TósakiDepartment of Pharmacology, University of Debrecen, Rex Ferenc utca 1, Debrecen, H-4002, Hungary.
Gábor HalmosDepartment of Biopharmacy, University of Debrecen, Rex Ferenc utca 1, Debrecen, H-4002, Hungary.
Brijesh RathiLaboratory for Translational Chemistry and Drug Discovery, Department of Chemistry, Hansraj College, University of Delhi, Delhi, India.
Pál HerczeghDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary.
Anikó BorbásDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary.
Ilona BereczkiDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, Debrecen, H-4032, Hungary. bereczki.ilona@pharm.unideb.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCannabidiol (CBD) and cannabigerol (CBG) are non-psychotropic phytocannabinoids that have significant, broad-spectrum therapeutic potential in a variety of pharmacological areas, but their unfavorable pharmacokinetics, such as extensive first-pass metabolism and low bioavailability, hinder their effective medical applications. Therefore, there is a great need for appropriate chemical modifications to improve their physicochemical properties. Incorporation of fluorine atom(s) at appropriate positions often improves the metabolic stability of the parent compound, increasing its bioavailability, and enhances its binding affinity to therapeutic targets, making fluorine a highly valuable element in modern drug development. Furthermore, amino functional groups may improve the water solubility and bioavailability of the compounds. Building on these principles, our strategy focused on introducing groups containing mono-, di-, and trifluoroethylamine or fluorinated aniline moieties into cannabinoids to improve their pharmacokinetic and pharmacological profiles.

methodsMannich-type reaction was applied, using commercially available 2-fluoroethylamine, 2,2-difluoroethylamine, 2,2,2-trifluoroethylamine, 3-fluoroaniline and 4-fluoroaniline as reagents. One or two oxazine rings with fluorine-containing side chains were condensed to the aromatic core of the cannabinoids, and the formation of mono- or disubstituted derivatives was controlled by the appropriate choice of reaction conditions. The biological activity of the derivatives was investigated in various relevant fields. RESULTS AND

conclusionOur findings indicate that aliphatic modifications positively influence pharmacokinetic parameters, including absorption, in contrast to aromatic groups, which increase lipophilicity and lead to decreased bioavailability. Among the modifications, the monosubstituted derivatives containing a single oxazine ring with an aliphatic fluorine-containing side chain, especially the mono- and trifluoroethyl moieties, proved to be the most promising. These modifications appeared particularly advantageous in the CBG series compared to the properties of the CBG parent compound. This may suggest that the presence of a phenolic OH group is beneficial for biological activity. Some of the derivatives showed anticancer potential against various tumor cell lines, while others modulated sebaceous lipogenesis, and certain compounds exhibited a notable antimalarial effect.

Indexed as

Anticancer effectCannabidiolCannabigerolFluorinated cannabinoidsMalariaMannich-type reactionSebaceous lipogenesis

Identifiers

PMID41645347
PMCPMC12964675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.